Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 single-arm study of ACT001 plus radiotherapy in newly diagnosed pediatric DIPG
CTR20232173Phase 2Completed
- Sponsor
- Tianjin Xinyi Shangde Biomedical Technology
- Start
- Sep 2023
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dimethylaminomicheliolide in diffuse intrinsic pontine glioma (DIPG), sponsored by Tianjin Xinyi Shangde Biomedical Technology. Started Sep 2023; status: completed.
02
Drugs
dimethylaminomicheliolide
03
Conditions
diffuse intrinsic pontine glioma (DIPG)
Beyond the preview
Go deeper on CTR20232173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232173.